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In insulin-dependent (type I) diabetes mellitus, blood
pressure is usually normal in the absence of nephro-
pathy, but after the onset of incipient nephropathy, as
indicated by microalbuminuria of 30-300 mg/24 h,
tends to increase, and increases further when the stage
of clinical nephropathy (proteinuria > 300 mg/24 h)
and renal failure have been reached [1,2]. In non-
insulin dependent (type II) diabetes mellitus, hyperten-
sion may precede diabetes, but is further aggravated
by nephropathy. Compared with the general popula-
tion, relative mortality of cardiovascular disease is
increased 2.5- to 7.2-fold in patients with both diabetes
mellitus and hypertension [3,4] and up to 37-fold with
clinical nephropathy [5,6]. Therefore, proteinuria is a
prognostic index of overriding importance.
In the 35% of patients with type I diabetes mellitus
who develop nephropathy, persistent microalbuminu-
ria ('incipient nephropathy') appears 5-10 years after
the clinical onset of diabetes. It will then progress
within the following 5-10 years to the stage of overt
nephropathy, and within a further 5-10 years to end-
stage renal failure [2,7]. In patients with type II diabetes
mellitus, the clinical presentation of diabetes or diabetic
nephropathy and the onset of hypertension are often
dissociated in time. Nevertheless, once nephropathy is
present, an elevated blood pressure may also promote
and accelerate the development of renal failure [8].
Antihypertensive therapy with different types of
drugs will decrease microalbuminuria or overt pro-
teinuria and retard progression of nephropathy, and
usually slow the decline in glomerular filtration rate in
initially non-azotaemic or mildly azotaemic nephro-
pathy [2,6,9-13]. Antiproteinuric and renoprotective
effects were initially observed with conventional antihy-
pertensive therapy, including diuretics and j?-blockers
[9,10]; the exception was monotherapy with diuretics,
which were suspected of accelerating diabetic nephro-
pathy [14]. Concerning the choice of antihypertensive
agents, a new argument has been introduced by experi-
mental studies [15] in diabetic animals, which suggested
disparate renoprotective effects of different antihyper-
tensive drugs. These experiments were not confirmed
by all subsequent investigations [16]. In particular, the
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possibility of drug-specific differences between the vari-
ous classes of antihypertensive agents with respect to
their antiproteinuric action in man has remained
controversial.
Changes in intrarenal haemodynamics and mesang-
ial metabolism, rather than systemic arterial pressure,
are the proximate determinants of drug-induced effects
on renal function. The potential of a reduction in
systemic blood pressure to decrease glomerular capil-
lary pressure may be enhanced by drugs which prefer-
entially dilate efferent, as opposed to afferent,
glomerular arterioles, such as ACE inhibitors [17];
while it may be antagonized by preferential afferent,
as opposed to efferent, glomerular vasodilatation,
which occurs with some calcium antagonists [18]. On
the other hand, one must also consider the possibility
of non-haemodynamic actions; certain calcium antag-
onists may inhibit renal hypertrophy associated with
diabetes mellitus [19]; other calcium antagonists and
ACE inhibitors may beneficially influence mesangial
metabolism [19,20]; and finally, ACE inhibitors may
decrease glomerular permeability for proteins [21].
Many of these studies were carried out in type I
diabetes mellitus, but it is likely that the results can be
extrapolated to patients with type II diabetes mellitus.
To explore further the possibility of a differential
effect of antihypertensive agents on albuminuria in
patients with diabetes mellitus, we carried out a meta-
analysis [22] of published studies in such patients with
microalbuminuria or overt proteinuria, including only
studies where proteinuria had been treated for 4 or
more weeks with antihypertensive drugs. This analysis
showed that proteinuria decreased more in patients
treated with ACE inhibitors than those treated by
conventional therapy (diuretic and/or /?-blocker) or
calcium antagonists; while it tended to increase on
nifedipine, despite a similar average reduction in blood
pressure (Table 1). Based on linear regression analysis,
ACE-inhibition-induced reduction in proteinuria cor-
related with the decrease in blood pressure (r = 0.58,
P< 0.0001); the decrease in proteinuria averaged
- 30% at zero blood pressure change, and varied 1.5%
for each percentage point of blood pressure change
(Figure 1). On conventional therapy, proteinuria and
changes in blood pressure also correlated (r = 0.62,
P<0.02), but proteinuria diminished only after a blood
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Table 1. Synthesis of reported effects of different antihypertensive treatments on albuminuria-proteinuria in diabetic patients with incipient
or clinical nephropathy
Type of therapy Number of patients Average changes (%) in
Mean systemic blood pressure Urinary albumin or protein excretion
Conventional 131
(Diuretics and/or
0-Blockers)
ACE inhibitors 589
Ca antagonists
all 191
nifedipine 85
all except 106
nifedipine
diltiazem 52
+ verapamil
-10
- 1 5
- 1 3
- 1 3
- 1 2
- 1 7
- 1 7
- 5 2
- 4
+ 21
- 2 4
- 2 3
Change In 24 h-Urine
Albumin or Total Protein
100 -,
50
-50 -
-100 -I
-30 -20 -10 0
Change in Mean Blood Pressure, %
Symbol
•
X
0
Drug
ACE-lnhlbitor
Conventional
Ca-Antagonlst
N
45
14
18
r
0.58
0.62
0.02
P <
0.0001
0.02
N.S.
Fig. 1. Percentage changes in albuminuria or total proteinuria as
related to blood pressure changes in diabetic patients on different
antihypertensive drug treatments. Nif, nifedipine; N, number of
reported studies.
pressure reduction of more than 5%. Furthermore, the
slope was steeper (4% proteinuria change per percent-
age blood pressure change) than on ACE inhibitors.
In the patients treated with calcium antagonists,
changes in proteinuria were unrelated to changes in
blood pressure. Changes in proteinuria on all drugs
were unrelated to pretreatment proteinuria (Figure 2)
or blood pressure. These findings demonstrate the
predominance of drug-specific over systemic blood-
pressure-dependent mechanisms in the antiproteinuric
action of ACE inhibitors. In contrast, as the example
of nifedipine illustrates, drug-specific intrarenal effects
may antagonize a blood-pressure-dependent antipro-
teinuric action and sometimes even counteract the
effect of lowering systemic pressure.
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Fig. 2. Percentage changes in albuminuria or total proteinuria as
related to their pretreatment levels in diabetic patients on different
antihypertensive drug treatments. N, number of reported studies.
As ACE inhibitors exert a specific antiproteinuric
effect even without a change in systemic blood pressure,
they are superior to other agents in treating microalbu-
minuria and overt proteinuria in patients with diabetes
mellitus who are normotensive or borderline hypertens-
ive. On the other hand, when systemic blood pressure
is lowered by 10-20%, as it is desirable in hypertensive
patients, ACE inhibitors, conventional therapy, and
several calcium antagonists all have a distinct antipro-
teinuric action. Based on a recent report the combina-
tion of an ACE inhibitor and a calcium antagonist in
reduced doses may tend to be more effective with
regard to proteinuria and protection of renal function,
and may be better tolerated than the normal dose
when each drug is used alone [12]. The challenge
remains, however, to prove whether different antihy-
pertensive drugs also have a disparate effect on the
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long-term evolution of renal function, and most
importantly, on prognosis. This remains as yet unre-
solved, and until such information is available, the
approach to pharmacotherapy in diabetic nephropathy
must remain empirical.
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